Shire is to acquire rare disease company ViroPharma for $4.2 billion in a strategic move to boost its orphan drug portfolio. ViroPharma is a high growth, rare disease biopharma company ...
Brokers forecast strong growth but share price has been flat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback